MSFS
PLX icon

Main Street Financial Solutions’s Protalix BioTherapeutics PLX Stock Holding History

Main Street Financial Solutions’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$385K Buy
214,100
+85,000
+66% +$174K 0.03% 383
2025
Q3 		$287K Buy
+129,100
New +$210K 0.02% 504

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Main Street Financial Solutions's PLX Position: Q4 2025 in Review

Main Street Financial Solutions increased its Protalix BioTherapeutics (PLX) stake by 66% in Q4 2025, buying an estimated $174K and bringing the position to 214,100 shares worth $385K. The position accounts for 0.03% of the portfolio, ranked #383.

Main Street Financial Solutions first reported a position in PLX in Q3 2025 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold PLX as of Q4 2025.

  • Main Street Financial Solutions held 214,100 shares of Protalix BioTherapeutics worth $385K as of Q4 2025.
  • Main Street Financial Solutions bought 85,000 Protalix BioTherapeutics shares in Q4 2025, an estimated $174K.
  • Protalix BioTherapeutics made up 0.03% of Main Street Financial Solutions's portfolio in Q4 2025, its #383 holding.
  • Main Street Financial Solutions first reported a position in Protalix BioTherapeutics in Q3 2025 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2025.

Based on Main Street Financial Solutions's 13F filing for Q4 2025, filed 17 Feb 2026.